Altimmune, Inc.
ALT
$5.33
$0.224.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | -86.49% | -98.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | -86.49% | -98.62% |
| Cost of Revenue | -24.46% | -18.53% | -26.34% | 16.99% | 7.70% |
| Gross Profit | 24.46% | 18.53% | 26.35% | -17.21% | -9.83% |
| SG&A Expenses | 18.82% | 1.72% | 12.82% | 17.50% | 10.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.78% | -14.29% | -18.58% | 17.09% | 8.17% |
| Operating Income | 15.78% | 14.29% | 18.58% | -17.27% | -9.88% |
| Income Before Tax | 16.77% | 10.12% | 16.96% | 26.74% | -10.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.77% | 10.12% | 19.75% | 26.74% | -10.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.77% | 10.12% | 19.75% | 26.74% | -10.52% |
| EBIT | 15.78% | 14.29% | 18.58% | -17.27% | -9.88% |
| EBITDA | 15.76% | 14.21% | 18.36% | -17.75% | -10.31% |
| EPS Basic | 33.85% | 21.76% | 24.79% | 39.92% | 16.61% |
| Normalized Basic EPS | 33.85% | 21.74% | 22.16% | 1.12% | 16.60% |
| EPS Diluted | 33.85% | 21.76% | 24.79% | 39.92% | 16.61% |
| Normalized Diluted EPS | 33.85% | 21.74% | 22.16% | 1.12% | 16.60% |
| Average Basic Shares Outstanding | 25.79% | 14.88% | 6.70% | 21.93% | 32.54% |
| Average Diluted Shares Outstanding | 25.79% | 14.88% | 6.70% | 21.93% | 32.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |